6505--Hydralazine RFP

The Department of Veterans Affairs National Acquisition Center is soliciting proposals for Hydralazine HCL Tablets in seven line items across various strengths (10mg, 25mg, 50mg, and 100mg) and package sizes (100 and 1,000 tablets per bottle). This firm fixed-price requirements contract will serve multiple federal agencies including the VA, Department of Defense, Bureau of Prisons, and Indian Health Service, with estimated annual usage ranging from 5,481 to 103,773 bottles depending on the line item. Offerors must submit pricing for all line items across the base year and four one-year option periods, including a mandatory 0.5% Cost Recovery Fee, and must provide unique NDC numbers, FDA approvals, and comply with specified packaging and labeling requirements. The solicitation will be evaluated based on offerors' ability to meet these requirements and provide competitive pricing. The proposal due date has been extended to November 13, 2025, at 2:30 PM CST.

This opportunity is designated as a small business set-aside with a size standard of 1,300 employees, meaning only qualifying small businesses are eligible to submit proposals. McKesson Corporation and other vendors are listed as prime vendors through the Pharmaceutical Prime Vendor programs that will distribute the contract. While specific award values are not detailed in the solicitation, the contract encompasses significant annual volume commitments across multiple agencies and product strengths. The contract structure includes a base year with four one-year option periods, providing potential long-term supply commitments. Distribution will occur through existing Pharmaceutical Prime Vendor networks, ensuring broad accessibility across federal healthcare facilities nationwide.